Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations

AIDS

Volumn 17, Issue 6, 2003, Pages 809-814

  Skrabal, Katharina ^a   Trouplin, Virginie ^a   Labrosse, Béatrice ^a   Obry, Véronique ^a   Damond, Florence ^a   Hance, Allan J ^a   Clavel, François ^a   Mammano, Fabrizio ^a,b  

^a INSERM   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

Antiretroviral therapy; HIV 1; Plasma virus; Tropism

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CXCR4; DELAVIRDINE; DIDANOSINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ARTICLE; BLOOD SAMPLING; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA FLANKING REGION; DRUG DISTRIBUTION; DRUG METABOLISM; GENETIC CODE; GENETIC RECOMBINATION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR CLONING; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TARGET CELL; VIROGENESIS; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; POLYMERASE CHAIN REACTION; RECEPTORS, CCR5; RECEPTORS, CXCR4; RETROSPECTIVE STUDIES; TROPISM; VIRAL LOAD;

EID: 0037964387     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200304110-00005     Document Type: Article

References (27)

1. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999, 17:657-700.
2. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998, 280:1884-1888.
3. Schuitemaker H. Macrophage-tropic HIV-1 variants: initiators of infection and AIDS pathogenesis? J Leukoc Biol 1994, 56:218-224.
4. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, van Steenwijk RP, et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992, 66:1354-1360.
5. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993, 261:1179-1181.
6. Berger EA. HIV entry and tropism: the chemokine receptor connection. AIDS 1997, 11:S3-16.
7. Berger EA, Doms RW, Fenyo EM, Korber BT, Littman DR, Moore JP, et al. A new classification for HIV-1. Nature 1998, 391:240.
8. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997, 185:621-628.
9. Richman DD, Bozzette SA. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994, 169:968-974.
10. Delforge ML, Liesnard C, Debaisieux L, Tchetcheroff M, Farber CM, Van Vooren JP. In vivo inhibition of syncytium-inducing variants of HIV in patients treated with didanosine. AIDS 1995, 9:89-90.
11. Ercoli L, Sarmati L, Nicastri E, Giannini G, Galluzzo C, Vella S, Andreoni M. HIV phenotype switching during antiretroviral therapy: emergence of saquinavir-resistant strains with less cytopathogenicity. AIDS 1997, 11:1211-1217.
12. Equils O, Garratty E, Wei LS, Plaeger S, Tapia M, Deville J, et al. Recovery of replication-competent virus from CD4 T cell reservoirs and change in coreceptor use in human immunodeficiency virus type 1- infected children responding to highly active antiretroviral therapy. J Infect Dis 2000, 182:751-757.
13. Holtkamp N, Otteken A, Findhammer S, Miller V, Kurth R, Werner A. Unexpected coreceptor usage of primary human immunodeficiency virus type 1 isolates from viremic patients under highly active antiretroviral therapy. J Infect Dis 2000, 181:513-521.
14. McKinney RE, Jr, Johnson GM, Stanley K, Yong FH, Keller A, O'Donnell KJ, et al. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. J Pediatr 1998, 133:500-508.
15. Philpott S, Weiser B, Anastos K, Kitchen CM, Robison E, Meyer WA, 3rd, et al. Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy. J Clin Invest 2001, 107:431-438.
16. Barin F, Lahbabi Y, Buzelay L, Lejeune B, Baillou-Beaufils A, Denis F, et al. Diversity of antibody binding to V3 peptides representing consensus sequences of HIV type 1 genotypes A to E: an approach for HIV type 1 serological subtyping. AIDS Res Hum Retroviruses 1996, 12:1279-1289.
17. Delwart EL, Shpaer EG, Louwagie J, McCutchan FE, Grez M, Rubsamen-Waigmann H, Mullins JI. Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. Science 1993, 262:1257-1261.
18. Trouplin V, Salvatori F, Cappello F, Obry V, Brelot A, Heveker N, et al. Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay. J Virol 2001, 75:251-259.
19. Labrosse B, Brelot A, Heveker N, Sol N, Schols D, De Clercq E, Alizon M. Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J Virol 1998, 72:6381-6388.
20. Korber BT, Kunstman KJ, Patterson BK, Furtado M, McEvilly MM, Levy R, Wolinsky SM. Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain- derived sequences. J Virol 1994, 68:7467-7481.
21. Power C, McArthur JC, Johnson RT, Griffin DE, Glass JD, Perryman S, Chesebro B. Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences. J Virol 1994, 68:4643-4649.
22. Strizki JM, Albright AV, Sheng H, O'Connor M, Perrin L, Gonzalez-Scarano F. Infection of primary human microglia and monocyte-derived macrophages with human immunodeficiency virus type 1 isolates: evidence of differential tropism. J Virol 1996, 70:7654-7662.
23. Gartner S, Popovic M. Macrophage tropism of HIV-1. AIDS Res Hum Retroviruses 1990, 6:1017-1021.
24. He J, Chen Y, Farzan M, Choe H, Ohagen A, Gartner S, et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 1997, 385:645-649.
25. Staprans S, Marlowe N, Glidden D, Novakovic-Agopian T, Grant RM, Heyes M, et al. Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS 1999, 13:1051-1061.
26. Ostrowski MA, Chun TW, Justement SJ, Motola I, Spinelli MA, Adelsberger J, et al. Both memory and CD45RA+/CD62L+ naive CD4(+) T cells are infected in human immunodeficiency virus type 1-infected individuals. J Virol 1999, 73:6430-6435.
27. Pierson T, Hoffman TL, Blankson J, Finzi D, Chadwick K, Margolick JB, et al. Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1. J Virol 2000, 74:7824-7433.